Opinion|Videos|March 14, 2025
JAK V617F Monitoring and Risk Assessment Tools: Optimizing Treatment Decisions in MPN
Author(s)Daniel Landau, MD
An expert discusses how advances in JAK V617F monitoring have improved the assessment of disease status and guided treatment decisions and how risk assessment tools have transformed the ability to optimize treatment selection in patients with myeloproliferative neoplasms (MPNs).
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please discuss how advances in JAK V617F monitoring have empowered you to better assess disease status and guide treatment decisions.
- Please share how risk assessment tools have transformed your ability to optimize treatment selection in patients with MPNs.
Advertisement
Related to this article
TRE-515 could improve the durability of response in combination with KRAS inhibition in patients with advanced non–small cell lung cancer, investigators stated.
FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.
Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
The MUC16xCD3 bispecific antibody showed a 73% response rate in phase 1/2 trial; the sponsor announced plans for a potential registrational cohort and phase 3 trial.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
2
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
3
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
4
Telehealth May Offer a Path to More Equitable Myeloma Transplant Access
5